Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (January 2023)
28 slides from Revelation Biosciences's investor presentation, Jan 10, 2023
Slide 1: Developing innovative therapeutics to address unmet needs
Developing innovative therapeutics to address unmet needs Corporate Presentation / January 2023 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Therapeutic Development Pipeline
Therapeutic Development Pipeline Revelation has developed a robust pipeline of potential high-value products based on the activity of PHAD All current product candidates are based on PHAD. REVTx-100 and REVTx-300 are supported by preclinical data Therapeutic Candidate Discovery Preclinical Phase 1 P
Slide 4: PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications
Cytokine induction PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications Treatment of acute and chronic inflammatory disease such as AKI, CKD and NASH (REVTx-300) PHAD Modulation of Immune Response Prevention and treatment of healthcare associated infection via trained immunity ((
Slide 5: REVTx-100 For the Prevention of Healthcare Associated Infection
REVTx-100 For the Prevention of Healthcare Associated Infection
Slide 6: REVTx-100 Program Highlights
REVTx-100 Program Highlights Scientific Rationale 1. 2015 HAI and Antibiotic Use Prevalence Survey, CDC.gov Stimulation of the TLR4 TRIF pathway with REVTx-100: Augments immune cell recruitment, which increases pathogen clearance Downregulates the pro-inflammatory response allowing healing to take p
Slide 7: Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection
Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967 Study Design: Mice were pre-treated (24 and 48 hours) with vehicle
Slide 8: Pretreatment with PHADs Impart Protection from Gram Positive Bacterial Infection
Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection. n = 7 to 10 animals per group. Pre-treatment with MPLA and PHAD(s) demonstrated improved pathogen c
Slide 9: Biomarkers support the underlying mechanism of PHAD
Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection. n = 7 to 10 animals per group. Biomarkers (cytokines) support the underlying mechanism of PHAD Sign
Slide 10: The Impact of Surgical-Site Infections (SSI)
The Impact of Surgical-Site Infections (SSI) DOI:10.1001/jamasurg DOI:10.1086/676022 DOI: 10.1016/j.jamcollsurg.2016.10.029 ~€11bn represents the midpoint of the range discussed in WHO Global guidelines on the prevention of surgical site infection. Nov 2016 DOI: 10.1086/501572 Up to 30% Estimated SS
Slide 11: Total US Addressable Market for REVTx-100 is over 6.3M Annual Procedures
Total US Addressable Market for REVTx-100 is over 6.3M Annual Procedures Operations on the digestive system 3.8M Operations on the urinary system 567K Operations on the male genital system 360K Operations on the female genital system 1.6M Surgeries in Hospital-Based Ambulatory Surgery and Hospital I
Slide 12: REVTx-100 Development Plan
REVTx-100 Development Plan REVTx-100 has potential utility across multiple indications Revelation plans to develop REVTx-100 as a treatment for multiple indications through Phase 2 Plan to strategic license and/or partner for Phase 3 studies and commercialization Phase Target Indication1 Anticipated
Slide 13: REVTx-100 Phase 1a/1b Draft Clinical Study Design
REVTx-100 Phase 1a/1b Draft Clinical Study Design 6 cohorts/8 subjects per cohort randomized 1:1 placebo vs drug: Phase 1a: Healthy volunteers1 Phase 1b: Patients undergoing elective abdominal colorectal surgery 30 subjects randomized 1:1:1 placebo: low dose group: high dose group Cohorts 1-5 - sing
Slide 14: REVTx-300 For the Treatment of Acute and Chronic Kidney Diseases
REVTx-300 For the Treatment of Acute and Chronic Kidney Diseases
Slide 15: REVTx-300 Program Highlights
REVTx-300 Program Highlights 1. Zwirner, N. and Ziblat, A. 2017 doi: 10.3389/fimmu.2017.00025 2. Ismaeli, J. et. al. 2022 doi: 10.4049/jimmunol.168.2.926 3. Hernandez, A. et. al. 2019 DOI: 10.1097/CCM.0000000000003967 Chronic and acute organ disease (AKI, CKD, NASH, and myocarditis) propagated by in
Slide 16: REVTx-300 Reduces Fibrosis in Acute and Chronic Kidney Model (UUO in Rats)
REVTx-300 Reduces Fibrosis in Acute and Chronic Kidney Model (UUO in Rats) Composite data represents the average of 3 anatomically distinct depths (10 images / depth / rat / group = ~60-65% of renal cortical area) Renal cortical fibrosis, expressed as Collagen Volume Fraction (CVF; via quantitation
Slide 17: REVTx-300 Antifibrotic Effect Likely Mediated by Reduction in TGF-b
REVTx-300 Antifibrotic Effect Likely Mediated by Reduction in TGF-b Next Steps Conduct additional nonclinical studies to further evaluate REVTx-300 for AKI, CKD, and NASH Phase 1 clinical study in 2023 Normal TNF-a range = 5-75pg/mL 1,2 1. Yin, J., et. al. Changes and significance of inflammatory cy
Slide 18: TGF-b and fibrosis: therapies targeting TGF-b reduction
TGF-b has been correlated with fibrosis in multiple clinical populations, including acute kidney injury, chronic kidney disease, NASH, and myocarditis. TGF-b is also a driver of tumor growth, and increased levels have been observed in cancer patients.1,2,3,4 Multiple therapies targeting the reductio
Slide 19: AKI Epidemiology
AKI Epidemiology In the US, 1% of all hospital admissions have AKI on admission1 During hospitalization, the approximate incidence rate of acute kidney injury is 2 to 5% and it develops in up to 67% of patients admitted in the intensive care unit1 AKI is an important contributor to increased hospita
Slide 20: AKI as a Result of Cardiac Surgery
AKI as a Result of Cardiac Surgery DOI: 10.2147/IJNRD.S167477 DOI: 10.1097/ACO.0000000000000422 DOI: 10.214470/1678-9741-2018-0084 Up to 31% Of patients undergoing cardiac surgery with no prior CKD develop post operative AKI3 50% Death rate of patients that develop post operative AKI2 $42.6k Average
Slide 21: AKI and CKD Markets
AKI and CKD Markets 333,569 1,167,490 |_| 3,350,000 900,000 Hospital addmission with AKI @AKI during hospitalization =AKI during intensive care ™Cardiac Surgeries =CKD Patients 2 REVELATION BIOSCIENCES
Slide 22: REVTx-300 Development Plan
REVTx-300 Development Plan Phase Indication Anticipated Timing Use of Data Preclinical AKI (I/R) 2023 Support IND Preclinical CKD 2023 Support IND Preclinical NASH 2023 Support additional indication Phase 1a Healthy volunteer 2023 Support Phase 1b study for REVTx-100 and REVTx-300 Phase 1b AKI1 2024
Slide 23: REVTx-300 Phase 1a/1b Draft Clinical Study Design
REVTx-300 Phase 1a/1b Draft Clinical Study Design 6 cohorts/8 subjects per cohort randomized 1:1 placebo vs drug: Phase 1a: Health volunteers1 Phase 1b: Patients undergoing elective cardiac surgery 30 subjects randomized 1:1:1 placebo: low dose group: high dose group Cohorts 1-5 - single ascending d
Slide 24: REVTx-200 Intranasal Adjunct for Improved Intramuscular (IM) Vaccination
REVTx-200 Intranasal Adjunct for Improved Intramuscular (IM) Vaccination
Slide 25: REVTx-200 Program Highlights
REVTx-200 Program Highlights - Traditional IM Immunization Alone: Increased systemic antibodies (IgG) Systemic protection Weak mucosal antibodies (IgA) Poor mucosal protection Transmission still active IM Immunization + REVTx-200: Increased systemic antibodies (IgG) Systemic protection Improved muco
Slide 26: Financial Overview
> REVELATION Financial Overview ~ BAOESI@IIEINIGIESS
Slide 27: Financial Overview: Beneficial Holders and Cap Table
Beneficial holders Percent George Tidmarsh, M.D., Ph.D. (Chairman) 8.9% All other management 6.7% Total management 15.6% 5% or Greater George Tidmarsh, M.D., Ph.D. (Chairman) 8.9% AXA IM Prime Impact Fund 8.3% Cap Table Shares Common Stock 23,536,070 Public Warrants (REVBW) 10,511,597 Warrants1 12,0
Slide 28: Thank you!
For more information please visit www.revbiosciences.com Thank you!
Revelation Biosciences — Investor Presentation (January 2023) on 6ix